Save
Email
Print
Share
RSSBrowse News Stories
51 to 60 of 75 stories
view headlines only
-
COX-2 Product Offers Good And Bad News In 'Test Tube' Strokes
February 17, 2005 — Laboratory studies at Johns Hopkins have revealed that certain products of the enzymes COX-1 and COX-2 can both protect and damage the brain. The findings, published in the February 2005 issue of the ... > full story -
COX-2 Inhibitor Increases The Risk Of Heart Attack In Elderly Adults With No History Of Heart Attack
February 5, 2005 — New research published in the on-line version of the Annals of Internal Medicine today, documents an increased risk of heart attack with one of the COX-2 inhibitors used in elderly adults with no ... > full story -
Penn Researchers Add More Evidence To Demonstrate Role Of COX Inhibitors In Heart-Disease Risk
January 26, 2005 — In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease ... > full story -
Vioxx Went Mostly To Patients Who Didn't Need It, Stanford Researcher Says
January 23, 2005 — When Vioxx began being sold in 1999, it was touted for relieving pain without causing the gastritis and ulcers that some people developed from taking ibuprofen, naproxen and other painkillers known ... > full story -
Jefferson Scientists Find Zinc May Help Prevent Esophageal, Oral Cancers
January 10, 2005 — Cancer researchers at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have found that zinc treatment may help prevent esophageal and oral cancers ... > full story -
FDA Issues Public Health Advisory Recommending Limited Use Of Cox-2 Inhibitors
January 4, 2005 — The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products ... > full story -
Celecoxib Shows Surprising Activity Against Estrogen Receptors
December 20, 2004 — Six months of treatment with celecoxib (Celebrex) in women at risk of developing breast cancer results in the reduction of estrogen receptor expression in breast cells, a research team at The ... > full story -
What Should Celebrex And Bextra Patients Do? University Of Michigan Expert Says There Are Still Plenty Of Options
December 20, 2004 — Today's announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, ... > full story -
NIH Halts Use Of COX-2 Inhibitor In Large Cancer Prevention Trial
December 19, 2004 — The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer ... > full story -
Penn Epidemiological Study Shows Difference In Cardiovascular Effects Between Vioxx And Celebrex
December 6, 2004 — In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at ... > full story
Search ScienceDaily
Number of stories in archives: 137,427
more 
